STEP 10 randomised phase 3 trial of once-weekly semaglutide 2.4 mg versus placebo in adults with obesity and prediabetes: greater weight loss and reversion to normoglycaemia at 52 weeks. PICO summary and expert commentary.
Browsing: Therapeutics
Drug-class and individual-agent evidence: GLP-1 receptor agonists, SGLT2 inhibitors, and the major trials behind semaglutide, tirzepatide, and related therapies.
A 12-week pilot randomised trial in 30 adults with type 2 diabetes compared a very-low calorie diet, semaglutide, and their combination on weight, body composition, and beta-cell function. PICO summary and expert commentary.
Semaglutide 2.4 mg weekly was superior to placebo for physical functioning across the four 68-week STEP 1-4 trials. PICO summary and expert commentary.
A prespecified analysis of the SELECT trial reports semaglutide produced a mean weight reduction of 10.2 percent versus 1.5 percent for placebo, sustained over four years in adults with cardiovascular disease and obesity but without diabetes. PICO summary and expert commentary.
A pre-specified secondary analysis of the SELECT trial found that once-weekly semaglutide 2.4 mg modestly reduced a composite kidney endpoint versus placebo in adults with overweight or obesity and established cardiovascular disease, without diabetes. PICO summary and expert commentary.
Prespecified pooled analysis of the STEP-HFpEF program shows once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.
In the FLOW randomised controlled trial, weekly semaglutide reduced major kidney disease events and cardiovascular death in patients with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
A prespecified secondary analysis of the STEP-HFpEF programme found that semaglutide 2.4 mg lowered NT-proBNP and produced larger health-status gains in patients with higher baseline NT-proBNP. PICO summary and expert commentary.
A post hoc analysis testing whether machine-learning digital pathology reproduces pathologist scoring of liver biopsies in a phase II semaglutide NASH trial. PICO summary and expert commentary.
A prespecified FLOW subgroup analysis tested whether semaglutide’s kidney and cardiovascular benefit held with or without baseline SGLT2 inhibitor use in type 2 diabetes and CKD. PICO summary and expert commentary.